4D Molecular Therapeutics Will Host Investor Day October 21
The biotech firm will hold a presentation in New York City regarding its pipeline and clinical progress.
Updated on Oct. 5, 2026 in Biotech
Biotechnology firm 4D Molecular Therapeutics will host an investor day on October 21, 2026, in New York City. The event will begin at 10:30am ET and include company presentations, expert panels, and a live Q&A session.
Why it matters
The company is currently developing therapeutic candidates that have not yet received regulatory approval, making investor transparency and scientific panels crucial for market evaluation. This event provides a platform for the firm to detail its progress to stakeholders and medical professionals.
4D Molecular Therapeutics is advancing 4D-150 into Phase 3 trials for wet age-related macular degeneration and diabetic macular edema via single intravitreal injection. The company also maintains a candidate for cystic fibrosis, 4D-710, in its pipeline.
The players
4D Molecular Therapeutics
A biotechnology company headquartered in Emeryville, California, that focuses on the development of genetic medicines.
The details
The event will feature panel discussions with four retinal experts to evaluate the company's research trajectory. 4D Molecular Therapeutics, based in Emeryville, California, currently has no products that have received regulatory approval.
Timeline
The investor day is scheduled for October 21, 2026.
The live event begins at 10:30am ET.
Roadmap
The biotechnology sector continues to pivot toward single-injection genetic therapies, shifting the industry standard for treating chronic conditions like macular degeneration. This event positions the company to demonstrate its competitive viability against larger incumbents in the gene therapy space.
The outcomes of this investor day may influence the long-term funding and development timelines for potential new treatments for macular degeneration. Investors and stakeholders can utilize the Q&A session to better understand the company's commercialization path and clinical success probability.
The takeaway
The firm remains in the pre-approval phase for its entire product pipeline, emphasizing the importance of upcoming clinical trial results. Prospective stakeholders should monitor the presentation for updates on the Phase 3 status of 4D-150.
What happens next
An archived webcast of the October 21, 2026, investor day will be available online for one year following the event.
Further reading
Learn more about the latest industry developments at Biotech.
More information
To secure your spot, register for the investor day webcast registration.
